Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India’s Draft Pharma Policy Could Pass On April 30

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - The much-delayed draft pharmaceutical policy for India could be finalized by the end of the month, government sources told PharmAsia News.

You may also be interested in...



Pressure Rises To Pass India’s Draft Drug Policy

NEW DELHI - Indian Chemicals Minister Ram Vilas Paswan is making an all out effort to get the country's draft pharmaceutical policy cleared by the Group of Ministers in its next meeting

IP Protection Concerns Grow In India, PhRMA Says

Intellectual property protection in India is an increasing concern for industry following a year of regulatory action and inaction, according to the Pharmaceutical Research and Manufacturers of America

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL038093

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel